David Darby

Projects

Projects per year 2019 2020 2021 2022 2023 2024 2027

• 6 Finished
• 7 Active

Projects per year

Search results

• Active

  Active monitoring of cognitive function to detect longitudinal cognitive trajectories in people over the age of 50 with multiple sclerosis.

  Merlo, D., Darby, D. & Lechner-Scott, J.

  1/01/25 → 31/12/27

  Project: Research

• A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti- MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

  Darby, D.

  31/10/24 → 30/10/26

  Project: Research

• Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

  Darby, D.

  12/08/24 → 11/08/26

  Project: Research

• A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease

  Darby, D.

  29/02/24 → 27/02/26

  Project: Research

• A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease

  Darby, D.

  8/06/23 → 8/06/25

  Project: Research

• An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants with Mild to Moderate Alzheimer’s Disease

  Darby, D., Cao, T., Kyndt, C., Brodtmann, A. & Zeimer, H.

  19/05/23 → 19/05/25

  Project: Research

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects With Mild-to-Moderate Alzheimer’s Disease

  Darby, D.

  26/10/22 → 25/10/26

  Project: Research

• Finished

  A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients with Early-onset Alzheimer’s Disease (EOAD)

  Darby, D. & Stewart, N.

  15/11/22 → 14/11/24

  Project: Research

• A PHASE IB/IIA, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING DOSE, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFTEY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7126209 FOLLOWING INTRAVENOUS INFUSION IN PATIENTS WITH PRODROMAL OR MILD TO MODERATE ALZHEIMER'S DISEASE

  Darby, D. & Kerris, J.

  29/07/21 → 31/12/24

  Project: Research

• Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

  Darby, D. & Wilson-Lee, P.

  13/07/21 → 31/12/24

  Project: Research

• An Extension Study of ANAVEX2-73 in Patients with Mild to Moderate Alzheimer's Disease.

  Darby, D., O'Brien, T. & Burn, K.

  16/03/20 → 31/12/21

  Project: Research

• Active self-monitoring to prospectively detect treatment failure and define subclinical progression trajectories in multiple sclerosis: The ACTIVE-MS Program.

  Van Der Walt, A., Butzkueven, H., Jokubaitis, V., Kolbe, S., Vogel, A. P., Stankovich, J., Butler, E., Macdonell, R. A. L. & Darby, D.

  Trish Multiple Sclerosis Research Foundation

  1/01/20 → 31/12/23

  Project: Research

• Active Participatory Health Monitoring in people with Multiple Sclerosis to improve treatment outcomes (Active-MS)

  Butzkueven, H., Van Der Walt, A., Darby, D., Stankovich, J., Jokubaitis, V., Skibina, O., Marriott, M., Butler, E. & Gresle, M.

  Department of Health and Aged Care (Australia)

  1/07/19 → 30/06/24

  Project: Research